150 related articles for article (PubMed ID: 1378919)
1. Susceptibility of acute myelogenous leukemia blasts to lysis by lymphokine-activated killer (LAK) cells and its clinical relevance.
Archimbaud E; Thomas X; Campos L; Fiere D; Doré JF
Leuk Res; 1992; 16(6-7):673-80. PubMed ID: 1378919
[TBL] [Abstract][Full Text] [Related]
2. Effect of human interleukin 3 on the susceptibility of fresh leukemia cells to interleukin-2-induced lymphokine activated killing activity.
Cesano A; Lista P; Bellone G; Geuna M; Brizzi MF; Rossi PR; Pegoraro L; Oberholtzer E; Matera L
Leukemia; 1992 Jun; 6(6):567-73. PubMed ID: 1376379
[TBL] [Abstract][Full Text] [Related]
3. Susceptibility of adult acute lymphoblastic leukemia blasts to lysis by lymphokine-activated killer cells.
Archimbaud E; Thomas X; Campos L; Magaud JP; Fiere D; Doré JF
Leukemia; 1991 Nov; 5(11):967-71. PubMed ID: 1961038
[TBL] [Abstract][Full Text] [Related]
4. Conjugate formation by leukemic blasts from acute myeloid leukemia with cytotoxic lymphocytes.
Palucka AK; Porwit A; Reizenstein P
Leuk Lymphoma; 1993 Nov; 11(5-6):427-33. PubMed ID: 7907248
[TBL] [Abstract][Full Text] [Related]
5. In vitro susceptibility of acute leukemia cells to the cytotoxic activity of allogeneic and autologous lymphokine activated killer (LAK) effectors: correlation with the rate and duration of complete remission and with survival.
Lauria F; Raspadori D; Rondelli D; Ventura MA; Foà R
Leukemia; 1994 May; 8(5):724-8. PubMed ID: 8182932
[TBL] [Abstract][Full Text] [Related]
6. Possible mechanism of selective killing of myeloid leukemic blast cells by lymphokine-activated killer cells.
Oblakowski P; Bello-Fernandez C; Reittie JE; Heslop HE; Galatowicz G; Veys P; Wilkes S; Prentice HG; Hazlehurst G; Hoffbrand AV
Blood; 1991 May; 77(9):1996-2001. PubMed ID: 1708296
[TBL] [Abstract][Full Text] [Related]
7. GM-CSF enhances IL-2-activated natural killer cell lysis of clonogenic AML cells by upregulating target cell expression of ICAM-1.
Bendall LJ; Kortlepel K; Gottlieb DJ
Leukemia; 1995 Apr; 9(4):677-84. PubMed ID: 7723403
[TBL] [Abstract][Full Text] [Related]
8. Target lysis by human LAK cells is critically dependent upon target binding properties, but LFA-1, LFA-3 and ICAM-1 are not the major adhesion ligands on targets.
Quillet-Mary A; Cavarec L; Kermarrec N; Marchiol-Fournigault C; Gil ML; Conjeaud H; Fradelizi D
Int J Cancer; 1991 Feb; 47(3):473-9. PubMed ID: 1704356
[TBL] [Abstract][Full Text] [Related]
9. Expression of adhesion molecules on acute leukemic blast cells and sensitivity to normal LAK activity.
Raspadori D; Lauria F; Ventura MA; Rondelli D; Tura S
Ann Hematol; 1993 Nov; 67(5):213-6. PubMed ID: 7694662
[TBL] [Abstract][Full Text] [Related]
10. Increased susceptibility to lymphokine activated killer (LAK) lysis of relapsing vs. newly diagnosed acute leukemic cells without changes in drug resistance or in the expression of adhesion molecules.
Arienti F; Gambacorti-Passerini C; Borin L; Rivoltini L; Orazi A; Pogliani EM; Corneo G; Parmiani G
Ann Oncol; 1992 Feb; 3(2):155-62. PubMed ID: 1606087
[TBL] [Abstract][Full Text] [Related]
11. Susceptibility of human leukemia to allogeneic and autologous lymphokine-activated killer cell activity: analysis of 252 samples.
Teichmann JV; Ludwig WD; Thiel E
Nat Immun; 1992; 11(3):117-32. PubMed ID: 1392400
[TBL] [Abstract][Full Text] [Related]
12. Inducibility of lymphokine activated killer (LAK) cells in patients with acute myelogenous leukaemia in complete remission and its clinical relevance.
Archimbaud E; Bailly M; Doré JF
Br J Haematol; 1991 Mar; 77(3):328-34. PubMed ID: 2012757
[TBL] [Abstract][Full Text] [Related]
13. CD18/CD54(+CD102), CD2/CD58 pathway-independent killing of lymphokine-activated killer (LAK) cells against glioblastoma cell lines T98G and U373MG.
Komatsu F; Kajiwara M
Oncol Res; 2000; 12(1):17-24. PubMed ID: 11061342
[TBL] [Abstract][Full Text] [Related]
14. Prolactin increases the susceptibility of primary leukemia cells to NK and LAK effectors.
Oberholtzer E; Contarini M; Veglia F; Cossarizza A; Franceschi C; Geuna M; Provinciali M; Di Stefano G; Sissom J; Brizzi MF; Pegoraro L; Matera L
Adv Neuroimmunol; 1996; 6(3):233-47. PubMed ID: 8968423
[TBL] [Abstract][Full Text] [Related]
15. Selective targeting of human lymphokine-activated killer cells by CD3 monoclonal antibody against the interferon-inducible high-affinity Fc gamma RI receptor (CD64) on autologous acute myeloid leukemic blast cells.
Notter M; Ludwig WD; Bremer S; Thiel E
Blood; 1993 Nov; 82(10):3113-24. PubMed ID: 7693036
[TBL] [Abstract][Full Text] [Related]
16. Expression of surface adhesion molecules CD54 (ICAM-1) and CD58 (LFA-3) in adult acute leukemia: relationship with initial characteristics and prognosis.
Archimbaud E; Thomas X; Campos L; Magaud JP; Doré JF; Fiere D
Leukemia; 1992 Apr; 6(4):265-71. PubMed ID: 1375302
[TBL] [Abstract][Full Text] [Related]
17. Resistance of some leukemic blasts to lysis by lymphokine activated killer (LAK) cells.
Panayotides P; Porwit A; Sjögren AM; Wasserman J; Reizenstein P
Eur J Haematol; 1988 Apr; 40(4):362-7. PubMed ID: 3259192
[TBL] [Abstract][Full Text] [Related]
18. The high lysability by LAK cells of colon-carcinoma cells resistant to doxorubicin is associated with a high expression of ICAM-1, LFA-3, NCA and a less-differentiated phenotype.
Rivoltini L; Cattoretti G; Arienti F; Mastroianni A; Melani C; Colombo MP; Parmiani G
Int J Cancer; 1991 Mar; 47(5):746-54. PubMed ID: 1706327
[TBL] [Abstract][Full Text] [Related]
19. Potential role for non-HLA-restricted cytotoxic cells in the immune surveillance of acute leukemia.
Archimbaud E; Campos L; Vila L; Thomas X
Immunol Lett; 1993 Dec; 39(1):13-5. PubMed ID: 7511562
[TBL] [Abstract][Full Text] [Related]
20. Defective lymphokine-activated killer cell generation and activity in acute leukemia patients with active disease.
Foa R; Fierro MT; Cesano A; Guarini A; Bonferroni M; Raspadori D; Miniero R; Lauria F; Gavosto F
Blood; 1991 Aug; 78(4):1041-6. PubMed ID: 1868239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
